What is Adipotide?
Adipotide — also called FTPP, short for its full technical name CKGGRAKDC-GG-(D)(KLAKLAK)₂ — is a synthetic proapoptotic peptidomimetic. That's a fancy way of saying it's a lab-made molecule that mimics a protein and is designed to trigger programmed cell death (apoptosis) in a very specific place: the blood vessels that feed white fat tissue (white adipose tissue, or WAT).[4]
Researchers classify it as a metabolic research peptide because its primary area of study is obesity and body-fat reduction. It is a research compound only — not approved for human use.
How Adipotide Works
Think of white fat tissue like a city that needs a constant water supply to survive. The blood vessels feeding that city are the water pipes. Adipotide is designed to act like a targeted demolition crew that only dismantles pipes in fat-tissue neighborhoods — leaving the rest of the city untouched.
More precisely, the peptide has two functional parts joined together. One part (CKGGRAKDC) acts as a homing sequence — it seeks out and binds to a protein called prohibitin, which is found on the surface of blood vessel cells inside white fat tissue. The second part — (D)(KLAKLAK)₂, often called the KLA domain — is the killing sequence. Once the peptide docks onto fat-tissue vasculature, it triggers apoptosis in those vessel cells, cutting off the blood supply to the fat.[4]
Without a blood supply, the fat cells themselves die off, and the body reabsorbs the tissue. Researchers have compared this strategy to anti-angiogenic cancer therapy — instead of starving a tumor, it starves fat deposits.[6]
What the Research Shows
The most significant published study tested Adipotide in obese Old World monkeys — a primate model considered much closer to humans than rodents. The results, published in Science Translational Medicine, showed that treated monkeys experienced rapid weight loss, a measurable reduction in white adipose tissue confirmed by MRI and DEXA scanning, and improved insulin resistance — a key marker of metabolic health.[4]
At the doses researchers found optimal, the monkeys also showed predictable and reversible changes in kidney (renal proximal tubule) function — meaning kidney effects appeared but resolved after dosing stopped. This is an important safety signal that researchers continue to watch closely.[4]
A separate study explored a related approach: using nanoparticles loaded with the same KLA killing sequence and targeted to prohibitin in fat-tissue vasculature. In diet-induced obese mice, this nanoparticle formulation reduced body weight, lowered serum leptin (a hormone linked to fat mass), reduced ectopic fat in the liver and muscle, and raised serum adiponectin (a beneficial metabolic hormone) — without detectable liver toxicity. Interestingly, the nanoparticle version outperformed a direct Adipotide bioconjugate at low doses in that model.[6]
Taken together, these studies support the concept that selectively targeting fat-tissue vasculature can reduce white adipose tissue and improve metabolic markers, while highlighting that dose selection and kidney function monitoring are critical research considerations.[4][6]
What Adipotide Is Being Studied For
- Obesity — targeted reduction of white adipose tissue mass.[4]
- Insulin resistance — improving metabolic markers associated with obesity.[4]
- Metabolic syndrome — addressing dysfunctional adipose tissue and ectopic fat deposition in liver and muscle.[6]
- Anti-angiogenic fat targeting — understanding how cutting blood supply to fat compares with other anti-obesity strategies.[6]
How Adipotide Is Dosed in Research
Dosing protocols for Adipotide vary across published animal studies and depend on factors like species, body weight, and study duration. Because this is a research-only compound with no established human dosing, there are no universal guidelines. Researchers typically reference dosing from the primate study as a starting framework.[4] For a full breakdown of the dose ranges used in published research, see the dosage chart on this page. You can also use the calculator to explore weight-based research dose conversions.
Mixing and Storing Adipotide
Adipotide is typically supplied as a lyophilized powder (freeze-dried). To prepare it for research use, it is reconstituted — meaning a liquid is added to dissolve the powder. Bacteriostatic water (sterile water with a small amount of benzyl alcohol) is the most common choice because it prevents microbial growth and extends the usable life of the solution. Add the liquid slowly down the side of the vial — never shake it, as this can break down the peptide structure. Swirl gently until fully dissolved. Once reconstituted, store the vial in a refrigerator (2–8 °C) away from light, and use within a few weeks. Unopened lyophilized vials should be kept frozen (around −20 °C) until needed. Always label vials with the date of reconstitution. These are general peptide-handling best practices for laboratory research settings.
Sources
- PET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study. — Scientific reports, 2022. PMID 35414642.
- Fluorinated High-Valent Sn(IV) Porphyrins Show Remarkable Photodynamic Activity in Cancer Cells. — ChemMedChem, 2024. PMID 39017962.
- Evaluation of (4-[18F]Fluorophenyl)triphenylphosphonium ion. A potential myocardial blood flow agent for PET. — Molecular imaging and biology, 2011. PMID 20563755.
- A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. — Science translational medicine, 2011. PMID 22072637.
- Saturation-Tolerant Prescribed Control for Nonlinear Systems With Unknown Control Directions and External Disturbances. — IEEE transactions on cybernetics, 2024. PMID 37028066.
- A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. — Journal of controlled release : official journal of the Controlled Release Society, 2013. PMID 23871959.
EN
BR
ES
FR